share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K:重大事件
美股SEC公告 ·  08/15 10:47

Moomoo AI 已提取核心信息

Exicure, Inc., a biotechnology company, announced the adjournment of its Special Meeting of Stockholders originally convened on August 15, 2024. The meeting was adjourned due to the lack of a quorum, as proxies representing only about 49.4% of the outstanding shares entitled to vote were submitted, falling short of the majority requirement. The Special Meeting is rescheduled to reconvene virtually on August 19, 2024, at 9:00 a.m. Central Time. Stockholders are encouraged to vote as soon as possible via the Internet or by phone, with the record date for voting eligibility set as July 26, 2024. Proxies already submitted will remain valid for the adjourned meeting unless revoked. The company, which has suspended clinical and development activities, is currently exploring strategic alternatives to maximize shareholder value.
Exicure, Inc., a biotechnology company, announced the adjournment of its Special Meeting of Stockholders originally convened on August 15, 2024. The meeting was adjourned due to the lack of a quorum, as proxies representing only about 49.4% of the outstanding shares entitled to vote were submitted, falling short of the majority requirement. The Special Meeting is rescheduled to reconvene virtually on August 19, 2024, at 9:00 a.m. Central Time. Stockholders are encouraged to vote as soon as possible via the Internet or by phone, with the record date for voting eligibility set as July 26, 2024. Proxies already submitted will remain valid for the adjourned meeting unless revoked. The company, which has suspended clinical and development activities, is currently exploring strategic alternatives to maximize shareholder value.
生物技术公司Exicure宣布将原定于2024年8月15日召开的股东特别大会延期。由于提交的代理人代表的表决权仅占有投票权的未流通股份的约49.4%,未达到大多数要求,因此会议被推迟。特别会议已重新安排于2024年8月19日美国中部时间上午9:00在线重新召开。股东通过互联网或电话进行投票的截止日期为2024年7月26日。已提交的代理人将在延迟的会议上继续有效,除非被撤销。该公司已暂停临床和开发活动,目前正在探索战略选择以最大化股东价值。
生物技术公司Exicure宣布将原定于2024年8月15日召开的股东特别大会延期。由于提交的代理人代表的表决权仅占有投票权的未流通股份的约49.4%,未达到大多数要求,因此会议被推迟。特别会议已重新安排于2024年8月19日美国中部时间上午9:00在线重新召开。股东通过互联网或电话进行投票的截止日期为2024年7月26日。已提交的代理人将在延迟的会议上继续有效,除非被撤销。该公司已暂停临床和开发活动,目前正在探索战略选择以最大化股东价值。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息